Gastroenterology Review
eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
4/2025
vol. 20
 
Share:
Send email
Share:
abstract:
Original paper

Fecal butyric acid as a predictive biomarker of endoscopic remission in inflammatory bowel disease: a multicenter prospective study

Katarzyna Karłowicz
1
,
Konrad Lewandowski
1
,
Danuta Domżał-Magrowska
2
,
Renata Talar-Wojnarowska
2
,
Karolina Skonieczna-Żydecka
3
,
Wojciech Marlicz
4
,
Ewa Małecka-Wojciesko
2
,
Grażyna Rydzewska
1, 5

  1. Department of Gastroenterology and Internal Medicine, National Medical Institute of the Ministry of the Interior and Administration, Warsaw, Poland
  2. Department of Digestive Tract Diseases, Medical University of Lodz, Poland
  3. Department of Biochemical Science, Pomeranian Medical University, Szczecin, Poland
  4. Department of Gastroenterology, Pomeranian Medical University, Szczecin, Poland
  5. Collegium Medicum, Jan Kochanowski University, Kielce, Poland
Gastroenterology Rev 2025; 20 (4): 443–448
DOI: https://doi.org/10.5114/pg.2025.158047
Online publish date: 2025/12/17
View full text Get citation
 
PlumX metrics:
Introduction
Effective prediction of endoscopic remission is a key to optimizing ulcerative colitis (UC) management. While fecal calprotectin (FC) is widely used, its limitations highlight the need for complementary biomarkers. This study evaluated fecal butyric acid (C4) as a novel, non-invasive predictor of endoscopic remission in UC.

Aim
To assess the association between fecal C4 levels and endoscopic remission (Mayo score 0), and secondarily/also, the correlation between C4 and FC.

Material and methods
A multicenter, prospective study enrolled 100 UC patients between April 2021 and April 2023, including 26 in remission and 74 with active disease. Inclusion criteria were confirmed UC diagnosis for ≥ 1 year and stable therapy without medication changes. Fecal C4 was measured using mass spectrometry. Analyses included descriptive statistics, group comparisons, receiver operating characteristic (ROC) curve analysis, and Spearman correlation.

Results
Patients in remission had significantly higher fecal C4 levels (mean difference: 4.05 nM/mg; 95% CI: 2.44–5.71; p < 0.001) and lower Mayo scores. C4 showed excellent predictive performance (area under the curve (AUC) = 0.943; 95% CI: 0.897–0.980; p < 0.001), with 100% sensitivity and 86% specificity at a cutoff of 1.68 nM/mg. No significant correlation was found between C4 and FC.

Conclusions
Fecal C4 is a promising biomarker for predicting endoscopic remission in UC, offering high sensitivity and specificity. Its use may enhance clinical decision-making and support individualized treatment approaches. Further validation in larger cohorts is warranted to confirm these findings and establish its clinical utility.

keywords:

butyric acid, biomarker, ulcerative colitis, inflammatory bowel disease
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.